Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Net Margin (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Net Margin data on record, last reported at 360.68% in Q3 2025.

  • For Q3 2025, Net Margin rose 17936.0% year-over-year to 360.68%; the TTM value through Sep 2025 reached 19.63%, up 64973.0%, while the annual FY2024 figure was 242.74%, 95162.0% up from the prior year.
  • Net Margin reached 360.68% in Q3 2025 per STOK's latest filing, down from 169.95% in the prior quarter.
  • Across five years, Net Margin topped out at 71.19% in Q1 2025 and bottomed at 1237.2% in Q2 2023.
  • Average Net Margin over 4 years is 590.69%, with a median of 625.57% recorded in 2024.
  • Peak YoY movement for Net Margin: tumbled -47295bps in 2023, then skyrocketed 91631bps in 2024.
  • A 4-year view of Net Margin shows it stood at 786.32% in 2022, then dropped by -23bps to 963.56% in 2023, then skyrocketed by 95bps to 47.25% in 2024, then plummeted by -663bps to 360.68% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 360.68% in Q3 2025, 169.95% in Q2 2025, and 71.19% in Q1 2025.